WallStreetZenWallStreetZen

NYSEMKT: CANF
Can Fite Biopharma Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CANF

Based on 2 analysts offering 12 month price targets for Can Fite Biopharma Ltd

Min Forecast
$2.50+575.68%
Avg Forecast
$6.75+1,724.32%
Max Forecast
$11.00+2,872.97%

Should I buy or sell CANF stock?

Based on 2 analysts offering ratings for Can Fite Biopharma Ltd.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CANF stock forecasts and price targets.

CANF stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-04
lockedlocked$00.00+00.00%2025-09-16

1 of 1

Forecast return on equity

Is CANF forecast to generate an efficient return?

Company
N/A
Industry
94.4%
Market
344.94%

Forecast return on assets

Is CANF forecast to generate an efficient return on assets?

Company
N/A
Industry
25.8%

CANF earnings per share forecast

What is CANF's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$4.20
Avg 2 year Forecast
$1.29

CANF revenue forecast

What is CANF's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$3.8M+576.07%
Avg 2 year Forecast
$3.0M+436.43%
Avg 3 year Forecast
$106.1M+18,842.86%
CANF's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CANF revenue growth forecast

How is CANF forecast to perform vs Biotechnology companies and vs the US market?

Company
719.66%
Industry
294.06%
Market
58.97%
CANF's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CANF's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CANF vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CANF$0.37$6.75+1,724.32%Strong Buy
INDP$2.51N/AN/A
PLRZ$0.76N/AN/A
GRI$1.69$22.50+1,231.36%Buy
QLGN$2.73N/AN/A
View Top Biotech Stocks

Can Fite Biopharma Stock Forecast FAQ

Is Can Fite Biopharma Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NYSEMKT: CANF) stock is to Strong Buy CANF stock.

Out of 2 analysts, 1 (50%) are recommending CANF as a Strong Buy, 1 (50%) are recommending CANF as a Buy, 0 (0%) are recommending CANF as a Hold, 0 (0%) are recommending CANF as a Sell, and 0 (0%) are recommending CANF as a Strong Sell.

If you're new to stock investing, here's how to buy Can Fite Biopharma stock.

What is CANF's earnings growth forecast for 2025-2026?

(NYSEMKT: CANF) Can Fite Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 77.41%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 105.81%.

Can Fite Biopharma's earnings in 2025 is -$8,799,000.On average, 3 Wall Street analysts forecast CANF's earnings for 2025 to be -$16,671,839,347, with the lowest CANF earnings forecast at -$16,018,010,608, and the highest CANF earnings forecast at -$17,162,210,901.

In 2026, CANF is forecast to generate $5,098,911,981 in earnings, with the lowest earnings forecast at $4,898,954,649 and the highest earnings forecast at $5,248,879,981.

What is CANF's revenue growth forecast for 2025-2027?

(NYSEMKT: CANF) Can Fite Biopharma's forecast annual revenue growth rate of 719.66% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 294.06%, and it is also forecast to beat the US market's average forecast revenue growth rate of 58.97%.

Can Fite Biopharma's revenue in 2025 is $560,000.On average, 3 Wall Street analysts forecast CANF's revenue for 2025 to be $15,020,604,390, with the lowest CANF revenue forecast at $14,429,460,688, and the highest CANF revenue forecast at $15,460,986,611. On average, 3 Wall Street analysts forecast CANF's revenue for 2026 to be $11,918,091,809, with the lowest CANF revenue forecast at $11,449,937,736, and the highest CANF revenue forecast at $12,267,223,659.

In 2027, CANF is forecast to generate $420,862,576,249 in revenue, with the lowest revenue forecast at $404,358,161,495 and the highest revenue forecast at $433,240,887,316.

What is CANF's forecast return on assets (ROA) for 2025-2027?

(NYSEMKT: CANF) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 25.8%.

What is CANF's Price Target?

According to 2 Wall Street analysts that have issued a 1 year CANF price target, the average CANF price target is $6.75, with the highest CANF stock price forecast at $11.00 and the lowest CANF stock price forecast at $2.50.

On average, Wall Street analysts predict that Can Fite Biopharma's share price could reach $6.75 by Nov 4, 2026. The average Can Fite Biopharma stock price prediction forecasts a potential upside of 1,724.32% from the current CANF share price of $0.37.

What is CANF's Earnings Per Share (EPS) forecast for 2025-2026?

(NYSEMKT: CANF) Can Fite Biopharma's current Earnings Per Share (EPS) is $0.00. On average, analysts forecast that CANF's EPS will be -$4.20 for 2025, with the lowest EPS forecast at -$4.04, and the highest EPS forecast at -$4.33. In 2026, CANF's EPS is forecast to hit $1.29 (min: $1.23, max: $1.32).

What is CANF's forecast return on equity (ROE) for 2025-2027?

(NYSEMKT: CANF) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.